Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients

• Main Authors: Alexandre Le Marouille (Author), Emma Petit (Author), Courèche Kaderbhaï (Author), Isabelle Desmoulins (Author), Audrey Hennequin (Author), Didier Mayeur (Author), Jean-David Fumet (Author), Sylvain Ladoire (Author), Zoé Tharin (Author), Siavoshe Ayati (Author), Silvia Ilie (Author), Bernard Royer (Author), Antonin Schmitt (Author)
• Format: Book
• Published: MDPI AG, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Palbociclib is an oral CDK4/6 inhibitor indicated in HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy. Its main toxicity is neutropenia. The aim of our study was to describe the kinetics of circulating neutrophils from real-life palbociclib-treated patients. A popula...